Allogene Therapeutics IncALLO
Price$1.60

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $4.6M+20,990.9% YoYTTM through 30 Jun 2026
Net Income -$165.5MTTM through 30 Jun 2026
Free Cash Flow -$102.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%
Operating Margin-3,886.1%
Net Margin-3,566.7%

Returns

-62.3%ROE
-43.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio9.75x
Net Debt-$266.9Mnet cash position
Cash & Equivalents$38.6M

Quality Metrics

Altman Z-Score-2.62
Piotroski F-Score4 / 9
FCF Margin-2,211.2%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $0
Diluted EPS-$0.66TTM
'19'20'21'22'23'24'25
FY2025: $-0.87

Dividend

No dividend

Capital Allocation

Capex Intensity8.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.